Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes, with significant weight management effects. Whilst available on the NHS under strict eligibility criteria, many patients seek private prescriptions through digital health platforms such as Second Nature. Understanding Second Nature Mounjaro cost and what's included in comprehensive programmes is essential for informed decision-making. This article examines Mounjaro's mechanism, NHS and private access routes, Second Nature's structured programme, and comparative costs across UK providers, helping you navigate treatment options safely and effectively.

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a once-weekly injectable medication licensed in the UK for the treatment of type 2 diabetes mellitus. It belongs to a class of medicines known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual mechanism distinguishes Mounjaro from other GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic).

The drug works by mimicking two naturally occurring incretin hormones that regulate blood glucose and appetite. GLP-1 stimulates insulin secretion in response to food intake, suppresses glucagon release (which reduces glucose production by the liver), slows gastric emptying, and promotes satiety. GIP also enhances insulin secretion. Together, these actions lead to improved glycaemic control in people with type 2 diabetes and can result in significant weight reduction, though the exact mechanisms behind weight loss are multifactorial and not fully understood.

Clinical trials (SURMOUNT studies) have demonstrated that tirzepatide can lead to substantial weight loss alongside improvements in cardiovascular risk factors such as blood pressure and lipid profiles. The medication is administered subcutaneously once weekly using a pre-filled pen device. Treatment typically starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg increments every 4 weeks (to 5 mg, 7.5 mg, 10 mg, 12.5 mg) up to a maximum of 15 mg weekly, as tolerated.

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, which are typically mild to moderate and tend to diminish over time. More serious potential side effects include acute pancreatitis, gallbladder disease, dehydration, acute kidney injury, and increased heart rate. There is also a risk of hypoglycaemia when used with insulin or sulfonylureas, which may require dose adjustments of these medications. Tirzepatide is not recommended during pregnancy or breastfeeding, and effective contraception should be used during treatment. If you experience severe abdominal pain, persistent vomiting, or other concerning symptoms, seek urgent medical advice via NHS 111 or 999 if severe.

NHS Availability and Private Prescription Options

As of early 2025, Mounjaro is available on the NHS for the treatment of type 2 diabetes in adults who meet specific clinical criteria, typically when other glucose-lowering therapies have not achieved adequate control. For weight management, NHS provision is subject to strict eligibility criteria aligned with NICE guidance. Patients should check the current NICE Technology Appraisal for the most up-to-date criteria, which typically include specific BMI thresholds and the requirement for use within specialist weight management services.

In practice, NHS access for weight management is often restricted due to capacity constraints within specialist services and budgetary considerations. Access varies by region, as local Integrated Care Boards (ICBs) make commissioning decisions based on available resources. Patients interested in NHS treatment should speak to their GP about referral to Tier 3 or Tier 4 specialist weight management services where available.

Due to these limitations, many individuals are seeking private prescriptions through regulated online clinics and telehealth providers. Private provision offers faster access but comes at a significant cost. Patients considering private treatment should ensure they use a provider registered with the Care Quality Commission (CQC) in England (or equivalent regulators in Scotland, Wales, and Northern Ireland) and that prescriptions are issued by UK-registered healthcare professionals following a thorough clinical assessment.

It is essential to verify that the medication is sourced from licensed UK pharmacies registered with the General Pharmaceutical Council (GPhC) to ensure authenticity and safety. Patients should be aware that private treatment is not a substitute for comprehensive lifestyle modification and ongoing medical supervision. Additionally, there have been supply constraints for GLP-1 receptor agonists in the UK, which may affect availability in both NHS and private settings.

What's Included in Second Nature's Mounjaro Programme

Second Nature is a digital health platform that offers a structured weight management programme incorporating Mounjaro (tirzepatide) alongside behavioural support, nutritional guidance, and lifestyle coaching. The service provides a holistic approach to weight loss, recognising that medication alone is insufficient for sustainable results. This multicomponent approach is consistent with NICE guidance on obesity management (such as NICE Clinical Guideline 189).

The programme typically includes an initial clinical assessment conducted by a UK-registered prescriber, who reviews the patient's medical history, current medications, and suitability for tirzepatide. If deemed appropriate, a prescription is issued, and the medication is delivered directly to the patient's home from a registered UK pharmacy. Patients receive ongoing clinical monitoring, with regular check-ins to assess progress, manage side effects, and adjust dosing as needed.

In addition to medication, participants gain access to a dedicated health coach and a structured curriculum covering topics such as nutrition, physical activity, sleep, and stress management. The programme uses a mobile app to facilitate daily tracking, provide educational content, and foster peer support through moderated community groups. Nutritional guidance is tailored to individual preferences and may include meal plans, recipes, and advice on portion control and mindful eating.

Second Nature emphasises sustainable habit formation rather than restrictive eating patterns. The programme typically runs for 12 months, although this may vary depending on individual goals and clinical response. Patients are provided with injection training, advice on safe sharps disposal, and clear pathways for escalating any concerns about side effects to clinical staff. It's important to note that the programme cost includes both the medication and the behavioural support components.

Comparing Mounjaro Costs Across UK Providers

The cost of Mounjaro in the UK varies considerably depending on the provider, the dose prescribed, and whether additional services such as consultations and lifestyle support are included. As of early 2025, private prescription costs for tirzepatide typically range from approximately £150 to £300 per month, with prices generally increasing for higher doses (10 mg, 12.5 mg, and 15 mg weekly). These prices are subject to change and may be affected by market conditions and supply availability.

Second Nature's Mounjaro programme is positioned as a comprehensive package, with monthly costs generally in the region of £200 to £250, depending on the dose. This fee typically covers the medication, prescriber consultations, health coaching, app access, and educational resources. When comparing costs, patients should consider the additional support provided, as programmes that combine medication with behavioural interventions may support better long-term outcomes.

Other UK providers include established online pharmacies and telehealth platforms such as Boots Online Doctor, Superdrug Online Doctor, and specialist weight management clinics. Prices across these services are broadly comparable, though some may offer lower medication costs but charge extra for consultations or provide less structured behavioural support. Patients should be cautious of significantly cheaper offers, as these may indicate unregulated sources or counterfeit products.

Key considerations when comparing costs include:

• Regulatory status: Ensure the provider is CQC-registered and uses GMC-registered prescribers.

• Medication sourcing: Confirm that Mounjaro is supplied by a licensed UK pharmacy registered with the GPhC.

• Consultation quality: Assess whether initial and follow-up consultations are thorough and conducted by appropriately qualified clinicians.

• Additional support: Evaluate the availability of nutritional advice, coaching, and monitoring.

• Transparency: Look for clear pricing with no hidden fees.

Patients should also be aware that private treatment is an ongoing financial commitment, as research (SURMOUNT-4 trial) has shown that discontinuing tirzepatide often leads to weight regain if lifestyle changes have not been adequately embedded. It is advisable to discuss treatment duration and exit strategies with the prescribing clinician. For those unable to afford private treatment, exploring NHS pathways remains the most cost-effective option. If you experience side effects from any medication, report them through the MHRA Yellow Card scheme.

Frequently Asked Questions